Sign up
Pharma Capital

Ergomed appoints new chief executive

Dr Dan Weng joins on July 1 from EPS Holdings, a Tokyo-listed contract research business
The boardroom will have a new face

The pharma services and drug developer Ergomed Plc (LON:ERGO) has appointed a new chief executive.

He is Dr Dan Weng, who joins on July 1 from EPS Holdings, a Tokyo-listed contract research business.

He will take the reins from the company’s founder, Dr Miroslav Reljanovic, who will become executive vice-chairman.

“I'm very pleased to welcome Dan to the team to guide Ergomed forward as we seek to build on the strong growth of our CRO [contract research] and pharmacovigilance businesses,” said Reljanovic.

“I look forward to contributing to Ergomed's continued success as vice-chairman, focusing on our existing and future co-development deals, our pipeline products, and the broader strategy of the business."

View full ERGO profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.